SynthesisBMC infectious diseases2025
Prevalence and associated risk factors of human leishmaniasis in sub-Saharan Africa: an umbrella review.
Synthesis in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Community Drivers ofTropical medicine and infectious disease · 2026Article
- Determinants of visceral leishmaniasis among patients admitted to selected public hospitals in Guji and Borena Zones, southern Oromia, Ethiopia: An unmatched case-control study.Therapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeishmaniasis is a neglected tropical disease caused by the flagellate protozoa leishmania. Leishmaniasis has spread or reemerged in various countries, causing global health and economic problems. Thus, comprehensive information on the pooled prevalence of human leishmaniasis played an important role in reducing its impact.
objectiveThis review aimed to assess the pooled prevalence of human leishmaniasis and associated risk factors.
methodsA comprehensive search was conducted for potential articles using the Web of Science, PubMed, Science Direct databases, Semantic Scholar, and Google Scholar search. Seven relevant articles about leishmaniasis prevalence and related determinants were found for the final umbrella review. Utilizing Microsoft Excel, data was extracted using separate sheets for leishmaniasis prevalence and related factors. Version 17.0 of the STATA software was used for analyzing the extracted data. The contribution of each research to the final results was ascertained by a sensitivity analysis. Egger's test and a funnel plot were used to determine publication bias. Inverse of variance statistics were used to check for heterogeneity across studies; major heterogeneity was taken into consideration, and subgroup analysis and meta-regression analysis were used if the I
resultsThe systematic search yielded 8,534 articles, of which 7 studies were included in this umbrella review. The pooled prevalence of human leishmaniasis in this review was 19.54% (95% CI: 13.78-25.30), indicating significant variation in the prevalence of human leishmaniasis, with I
conclusionsThis umbrella review showed that human leishmaniasis is prevalent in sub-Saharan Africa. The reported increase in the incidence of human leishmaniasis emphasizes the necessity of better monitoring systems and infection control methods to lower the burden and spread of the disease in sub-Saharan Africa. Addressing the causes of human leishmaniasis and lowering its negative effects on public health also requires coordinated actions. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.